Clinical trials: Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal Carcinoma
Umbrella Biomarker-Guided Therapy in NPC
This is a phase 2, open-label, umbrella study, with the purpose to evaluate the therapeutic efficacy and safety of chemoradiotherapy in combination with immunotherapy and/or targeted treatment in high-risk locoregionally advanced…
- Trial name
- NCT04605562
- Testing
- GP+DDP, Palbociclib, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 206 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Neoplasms
PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive care.
- Trial name
- DIPPER (NCT03427827)
- Testing
- Camrelizumab
- Where
- 11 sites in China
- Volunteers
- 450 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma
At present, the treatment regimen of locally advanced nasopharyngeal carcinoma still needs to be further improved, and the focus of improvement lies in "replacing cisplatin with high-efficiency and low-toxicity treatment…
- Trial name
- NCT05341193
- Testing
- Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab, Bevacizumab+Toripalimab+gemcitabine, adjuvant with Toripalimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus concurrent chemoradiotherapy (CCRT) with CCRT alone in patients with locoregionally advanced nasopharyngeal carcinoma(NPC), in order to…
- Trial name
- NCT01872962
- Testing
- gemcitabine and cisplatin (Induction chemotherapy), IMRT and concurrent cisplatin
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma
This is a phase III randomized clinical trial of definitive radiotherapy plus EGFR blocker nimotuzumab versus radiotherapy plus cisplatin(CCRT) for nasopharyngeal carcinoma (NPC) patients with favorable response to induction…
- Trial name
- NCT04456322
- Testing
- RT plus Nimotuzumab, RT plus Cisplatin
- Where
- China
- Volunteers
- 381 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Carcinoma, Nasopharynx Cancer
- Trial name
- NCT07650266
- Testing
- Cemiplimab, Fianlimab
- Where
- 7 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Locally Advanced Nasopharyngeal Carcinoma
Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
The purpose of this study was to investigate the role of immunonutrion compared with standard nutrition in reducing oral mucositis in patients with locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT05892354
- Testing
- Enteral immunonutrition, Standard enteral nutrition
- Where
- 20 sites in China
- Volunteers
- 190 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Adebrelimab and Chemoradiotherapy in High-risk LANPC
This trial aims to study the role of Adebrelimab combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) for high-risk locoregionally advanced nasopharyngeal carcinoma(LANPC).
- Trial name
- NCT06349889
- Testing
- Adebrelimab
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma
This trial evaluated the efficacy of two adjuvant regimens following identical induction and concurrent chemoradiotherapy (IC+CCRT) in locoregionally advanced nasopharyngeal carcinoma (LANPC) patients with persistent EBV DNA…
- Trial name
- NCT07238569
- Testing
- Adebrelimab (PD-L1 inhibitor), Cisplatin (100mg/m2), Intensity-modulated radiotherapy
- Volunteers
- 516 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma
A total of 300 patients with pathologically confirmed Locoregionally advanced nasopharyngeal carcinoma were enrolled. Patients were randomly divided into two groups, with 150 patients in each group.
- Trial name
- NCT02907710
- Testing
- Endostar, DDP
- Where
- China
- Volunteers
- 300 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Neoplasms
Tisleilizumab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma
This trial intends to enroll patients with T4N1 or T1-4N2-3 (AJCC 8th) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT04870905
- Testing
- Tis-U-Sol
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Carcinoma by AJCC V8 Stage
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR).
- Trial name
- NCT05717790
- Testing
- Nimotuzumab, Gemcitabine, Cisplatin
- Where
- 9 sites in China
- Volunteers
- 288 people
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, Malnutrition
The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients
The purpose of this study is to study the function of pre-albumin, retinol conjugated protein and transferrin in early malnutrition detecting and nutritional status dynamic monitoring for local advanced nasopharyngeal carcinoma…
- Trial name
- NCT03240835
- Testing
- cisplatin and docetaxel, IMRT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhao Chong
Nasopharyngeal Carcinoma
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
This is a Phase II Randomized Trial to Compare Paclitaxel combined with DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03047265
- Testing
- Paclitaxel, Cisplatin
- Where
- China
- Volunteers
- 164 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, De-escalation Therapy
Reduced-dose RT With/Without CCT Versus Standard CCRT for High-risk LANPC Who Achieved CR Post Induction Chemotherapy
This prospective trial aims to enroll patients with high-risk stage III-IVA (AJCC 8th, except T3N0) locoregionally-advanced nasopharyngeal carcinoma (LANPC).
- Trial name
- NCT06092957
- Testing
- Cisplatin-based induction chemotherapy, Full course of PD-1/PD-L1 blockades, Reduced-dose IMRT
- Where
- China
- Volunteers
- 504 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma
Nedaplatin in Treatment for Nasopharyngeal Carcinoma
To evaluate the efficacy of induction chemotherapy with nedaplatin, docetaxel and 5-Fluorouracil followed by concurrent nedaplatin combined with radical radiotherapy in locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT04834206
- Testing
- Docetaxel, nedaplatin, fluorouracil, IMRT, Nedaplatin
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Nasopharyngeal Carcinoma, Nasopharyngeal Cancer
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Nasopharyngeal carcinoma (NPC) is commonly observed in southern China, particularly in the Pearl River delta area and the Xijiang River basin in the Guangdong and Guangxi provinces, with an incidence rate as high as 25-50 per…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Cancer, Nasopharynx Cancer
- Trial name
- NCT04004871
- Testing
- Nab-paclitaxel, Cisplatin and Fluorouracil, concurrent chemoradiotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guangxi Medical University
Nasopharyngeal Carcinoma
Concurrent Nimotuzumab Versus Cisplatin With Radiotherapy for Locoregionally Advanced NPC
The study is to evaluate whether concurrent nimotuzumab could decrease the severe acute treatment-related toxicities compared with concurrent chemoradiotherapy for locoregionally advanced NPC.
- Trial name
- NCT02012062
- Testing
- TPF neoadjuvant chemotherapy, Concurrent chemotherapy with cisplatin during radiotherapy, Concurrent nimotuzumab during radiotherapy
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
The purpose of this study is to compare the survival and toxicity of GP (gemcitabine and cisplatin) vs. PF (cisplatin and fluorouracil) as induction chemotherapy combined with concurrent chemoradiotherapy (CCRT) for…
- Conditions
- Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Nasopharyngeal Diseases, Head and Neck Neoplasm
- Trial name
- NCT03840421
- Testing
- gemcitabine and cisplatin, cisplatin and fluorouracil, IMRT
- Where
- China
- Volunteers
- 468 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Cancinoma (NPC)
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
Based on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified.
- Trial name
- NCT07496190
- Testing
- Becotatug vedotin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University